Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global immunology market was valued at US$ 92.84 billion in 2021 and is expected to register a revenue CAGR of 8.2% to reach US$ 188.70 billion by 2030.

Immunology Market Fundamentals 

The immune system protects an individual from infection in different ways. If the immune system of an individual is non-functional, they can develop various diseases, such as autoimmunity, allergies, and cancer. Autoimmune disorders develop when the immune system attacks the body that it is supposed to defend. People with autoimmune diseases have a deficiency in their immune system that prevents them from keeping "self" molecules apart from "non-self" or "foreign" molecules. Numerous laboratory tests are available in immunology to identify autoimmune disorders.

[43545434]

Immunology Market Dynamics

Rising prevalence of infectious diseases, such as hepatitis and AIDS, is driving revenue growth in the immunology market. Immunomodulators are used in the treatment of infectious disorders, such as AIDS and hepatitis.

Immunology Market Ecosystem

The global immunology market is analyzed based on four parameters: drug class, disease indication, distribution channel, and region.

Immunology Market by Drug Class

[23432535]

Based on the drug class, the global immunology market is segmented into monoclonal antibodies (mAb), polyclonal antibodies (pAb), fusion proteins, immunosuppressants, and others. 

The monoclonal antibody (mAb) segment is expected to dominate the global immunology market during the forecast period. This can be attributed to established clinical efficiency of monoclonal antibodies, such as adalimumab and rituximab, in the treatment of rare and chronic conditions and autoimmune diseases. In addition, increasing number of approvals for mAbs for the treatment of various conditions favor segmental revenue growth. 

Immunology Market by Disease Indication

Based on the disease indication, the global immunology market is segmented into rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, inflammatory bowel disease, prophylaxis of organ rejection, and others. 

The rheumatoid arthritis segment dominates the market in terms of revenue share, owing to rising number of patients undergoing treatment, leading to high demand for drugs required in the treatment of rheumatoid arthritis.

Immunology Market by Distribution Channel

Based on the distribution channel, the global immunology market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. 

The retail pharmacy segment accounts for the largest revenue share in the global immunology market due to increasing number of hospitalizations and visits to physicians by patients suffering from immunological or autoimmune disorders. 

Immunology Market by Region

Based on the region, the global immunology market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). 

North America accounts for the largest revenue share of the global market for immunology. This can be attributed to availability of superior healthcare reimbursement policies and development of advanced technologies. 

Europe is the second-largest region in terms of market value due to the ease of availability of immunology drugs and high affordability of therapy. 

The significantly large patient pool, improving economy, growing government initiatives, and increasing awareness among people about health are expected to lead to rapid revenue growth in the Asia Pacific immunology market during the forecast period.

Immunology Market Competitive Landscape

The prominent players operating in the global immunology market include:

• Pfizer, Inc.
• AbbVie Inc. 
• Janssen Global Services, LLC (Johnson & Johnson)
• F. Hoffmann-La Roche Ltd.
• Amgen Inc. 
• Novartis AG 
• Astellas Pharma Inc. 
• UCB SA
• Bristol-Myers Squibb Company
• Merck Sharp & Dohme Corp.
• Eli Lilly and Company

Immunology Market Strategic Developments

• In June 2022, the U.S. FDA approved the usage of RIABNITM (rituximab-arrx) for people with moderately to severely active rheumatoid arthritis (RA) who have not shown satisfactory outcomes from one or more TNF antagonist medications. Amgen is working on eleven biosimilars, some of which are medicines for inflammatory diseases and cancer.
• In May 2022, AbbVie and Cugene announced a worldwide license option agreement for CUG252, a potential best-in-class Treg-selective IL-2 mutein. This agreement was intended to treat autoimmune and inflammatory diseases. If AbbVie exercised the option, Cugene was expected to be compensated with a license option exercise payment, development, and regulatory milestone payments, and a US$ 48.5 million upfront payment.
• In September 2021, Eli Lilly & Company and Lycia Therapeutics established a multiyear research partnership and license agreement to investigate, create, and market fresh targeted therapeutic candidates. The companies were expected to use Lycia Therapeutics' LYTAC (lysosomal targeting chimaera) platform to find and develop medication candidates for up to five targets in Eli Lilly & Company's therapeutic areas, such as immunology and pain.
• In July 2020, Janssen Pharmaceutical reported that the U.S. FDA had authorized STELARA (ustekinumab) for an additional indication as a treatment for young patients (ages 6 to 11) who struggle with skin lesions or plaques linked to moderate to severe plaque psoriasis (PsO). Interleukin (IL)-12 and IL-23, two cytokines believed to be important in controlling the excessive inflammatory response in a variety of autoimmune disorders, such as PsO, are the targets of STELARA.

Frequently Asked Questions About This Report